Investors

Event Calendar

 

Upcoming Events

Annual General Meeting: Thursday 27 June, 2024

Venue: TBC // Registration Deadline: Thursday 13 June 2024
Read more


    Past Events

    ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

    December 10, 2021

    Read more

    ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

    October 23, 2021

    Read more

    ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    September 20, 2021

    Read more
    1 3 4 5 6 7 32

    General Meetings

    ObsEva Annual General Meeting 2023

    June 29, 2023

    Read more

    ObsEva Annual General Meeting 2022

    May 18, 2022

    Read more
    1 2 3 4
     
     

    Sign up for news

     
     

      * Type:


      InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












      Read our privacy policy here.


       

      Are you sure you want to leave ObsEva.com?

      We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

      Continue to link

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue

      Disclaimer

      Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

      Continue